News from pharmaceutical companies and other related healthcare organizations
Corcept Therapeutics recently announced the initiation of a clinical trial – called Momentum – to examining the prevalence of endogenous hypercortisolism (Cushing’s syndrome) in patients with resistant hypertension. The trial will enroll 1,000 patients across 45
Corcept Therapeutics moves forward with a groundbreaking advertising campaign to increase awareness of Cushing’s by focusing on the results of recent research conducted by the company that shows that almost 25% of people with difficult-to-treat Type-2 diabetes may, in fact, have Cushing’s Syndrome, which could, also be the underlying cause of the diabetes.
We often scan the pituitary universe and report on the latest drug developments, new potential therapies, and engaging clinical cases and resources. We hope this knowledge helps people gain more insight into these complicated diseases and the fascinating medical/scientific discovery, research, and diagnosis world.
From Jorge D. Faccinetti, co-founder and chief editor: Why can’t we address some of the most critical issues affecting healthcare today? These are not just other people’s problems. They affect us, our doctors, and our
From the desk of Jorge D. Faccinetti – chief editor and co-founder – I am thrilled to announce that Pituitary World News co-founder Dr. Lewis Blevins has been working on a new book on Cushing’s
Spain and Spanish-speaking countries have been our focus as we seek to develop more content in Spanish for our edition of Pituitary Word News in Español. Today’s podcasts covers part of the conference and shares my conversations with three world-renowned Spanish endocrinologists.
In today’s podcast, we talk with Giacomo Chiesi, Head of Global Rare Diseases at the Chiesi Group, where he leads a team in developing and marketing treatments for rare and ultra-rare diseases.
From J D Faccinetti, Co-founder and Chief Editor – When you deal with a chronic pituitary disease, you get close to your medications, just like you would to a friend. This was my experience with
From the desk of J. D. Faccinetti, co-founder – We are big fans; collaboration works. Our experience and research suggest that when collaboration between organizations is strong, learning improves, and outcomes…
By J D Faccinetti, co-founder – In a three-day conference packed with thousands of scientists, endocrinologists, industry, and researchers, ENDO 2023 Conference presented a comprehensive review of the latest in pituitary disease advances, treatment, management, developments,